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Abstract The purpose of our study was to establish the
frequency and distribution of the four most common BRCA1
mutations in Polish general population and in a series of
breast cancer patients. Analysis of the population frequency of
5382insC (c.5266dupC), 300T >G (p.181T >G), 185delAG
(c.68_69delAG) and 3819del5 (c.3700_3704del5) mutations
of the BRCA1 gene were performed on a group of respectively
16,849, 13,462, 12,485 and 3923 anonymous samples
collected at birth in seven Polish provinces. The patient group
consisted of 1845 consecutive female breast cancer cases. The
most frequent BRCA1 mutation in the general population
was 5382insC found in 29 out of 16,849 samples (0.17%).
300T >G and 3819del5 mutationswerefoundinrespectively
11 of 13,462 (0.08%) and four of 3923 (0.1%) samples. The
population prevalence for combined Polish founder 5382insC
and 300T >G mutations was 0.25% (1/400). The frequencies
of 5382insC and 300T >G carriers among consecutive breast
cancer cases were, respectively, 1.9% (35/1845) and 1.2%
(18/1486).Comparingthese data withthe population frequen-
cy, we calculated the relative risk of breast cancer for
5382insC mutation at OR = 17 and for 300T >G mutation at
OR = 26. Our results, based on large population studies, show
high frequencies of founder 5382insC and 300T >G BRCA1
mutations in Polish general population. Carriage of one of
these mutations is connected with a very high relative risk of
breast cancer.
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Introduction
Germline mutations in BRCA1 gene are transmitted in an
autosomal dominant manner with high penetrance, which
predisposes individuals to breast and ovarian cancer. The
carrier frequency in general populations ranges between 1/
40 and 1/800 and depends on founder effect specific for
distinct populations. In Poland, the founder BRCA1
mutations are 5382insC, originated in the Baltic area,
and 300T >G, widely spread throughout Central Europe.
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mutations in Poland (Gorski et al. 2000; Grzybowska et al.
2000; Jasinska and Krzyzosiak 2001;P e r k o w s k ae ta l .
2003; Ratajska et al. 2008; Van Der Looij et al. 2000a).
The same two founder mutations were described in Germans,
LatviansandCzechs(Csokayetal.1999; Elsakov et al. 2010;
Meindl et al. 2002). Other recurrent mutations in Polish
population were described as founders in some European
populations: 3819del5 (founder in Czech Republic),
185delAG (Ashkenazi Jews), 4153delA (Lithuania) and
their distribution is variable in different historical regions
of Poland.
The highest frequency of BRCA1/2 founder mutations is
recorded in Ashkenazi Jews (2–2.5%) and Icelanders (0.6%)
(Neuhausen et al. 2009; Struewing et al. 1997). Even though
founder effect was also recorded in other populations, in
most European and American countries BRCA1/2 mutations
occur with the lower frequency of 0.06–0.24% (Antoniou et
al. 2002;F o r de ta l .1995; Whittemore et al. 1997, 2004). So
far, only a few works were based on direct measurements of
mutation occurrence but they were usually provided in
ethnically and genetically distinct small populations (Gorski
et al. 2005;M a l o n ee ta l .2006; Metcalfe et al. 2010;
Struewing et al. 1997; Van Der Looij et al. 2000b). To date,
most investigators estimated BRCA1/2 gene mutation fre-
quency indirectly by combining data from population-based
series of breast and ovarian cancer patients with estimates of
the cumulative risk of these cancers in carriers and non-
carriers or on the basis of cancer mortality among relatives of
affected women (Ford et al. 1995, Risch et al. 2006,
Whittemore et al. 1997 and 2004).
The purpose of our study was to establish the frequency
and spectrum of BRCA1 mutations in Polish general
population and consecutive breast cancer cases. Our choice
of the four BRCA1 alleles analysed in the present study
reflects their high prevalence among Polish breast and/or
ovarian cancer families and is based on the results of
previous research (Brozek et al. 2009; Gorski et al. 2000;
Grzybowska et al. 2000; Janiszewska et al. 2003; Jasinska
and Krzyzosiak 2001; Perkowska et al. 2003; Ratajska et al.
2008; Van Der Looij et al. 2000a, b).
Materials and methods
Analysisofthefrequencyof5382insC(c.5266dupC),300T>G
(p.181T >G), 185delAG (c.68_69delAG), and 3819del5
(c.3700_3704del5) mutations of BRCA1 gene were performed
on groups of respectively 16,849, 13,462, 12,485 and 3923
anonymous samples collected at birth. We made use of dried
blood spots on filter paper applied for neonatal screening for
phenylketonuria. The samples were collected from hospitals
spread over the area of seven voivodeships of Poland. The
population of these voivodeships equals 58% of the whole
Polish population.
Consecutive, newly diagnosed female breast cancer
cases were collected without regard to age or family history
of breast and ovarian cancer in two voivodeships, Malo-
polska and Mazowsze. The patient study group included
1845 breast cancer patients.
Dried blood spots on filter paper were fragmented into
2 mm pieces. After their denaturation at 95°C in 25 μlH 2O,
samples were subjected to 20 cycles of PCR reaction. Next,
PCR product was centrifuged and 40 cycles nested PCR
amplification were performed. The PCR primer sequences
were: exon 2 Forward GAAGTTGTCATTTTA
TAAACCTTT, Reverse TGTCTTTTCTTCCCTAGTATGT,
exon 5 Forward GTTGTGAGATTATCTTTTCATGGC,
Reverse CTTCCAACCTAGCATCATTACCA, exon 11
Forward GAGTCCTAGCCCTTTCACCCATAC, Reverse
GTGATGTTCCTGAGATGCCTTTG, exon 20 Forward
ATATGACGTGTCTGCTCCACC, Reverse AAT
GAAGCGGCCCATCTC. Details concerning amplification
conditions are available upon request.
In the groups of consecutive breast cancer cases DNA
was extracted from peripheral blood lymphocytes in
accordance with standard procedure. The contributions the
mutation detection methods made to analysis pathogenic
allels and representative examples of mutations detected by
various methods are shown in Fig. 1. Mutation analyses
were done using a combination of different screening
methods. For detection of mutation 185delAG located in
exon two and 3819del5 located in exon 11 of BRCA1 gene
single strand conformation polimorphism (SSCP) and
denaturing high performance liquid chromatography
(DHPLC) technique were used. For identification of change
T >G in position 300 (exon 5) the restriction fragment
length polymorphism (RFLP) or DHPLC were taken. For
the last mutation tested within this study (5382insC, exon
20) an Allele Specific Oligonucleotide PCR (ASO-PCR) or
DHPLC techniques were carried out. The sensitivity of
applicated techniques ranges from 70% for SSCP to 98%
for DHPLC.
The prevalence of each mutation was derived from the
ratio of positive samples to the total number of tested
samples. Comparisons between groups for statistical
significance were performed by the use of χ
2 and
Fisher’s exact tests, as appropriate. P values less than
0.05 were considered statistically significant. For breast
cancer relative risk estimation, we compared the propor-
tions of the prevalence of the most common BRCA1
founder mutations in consecutive breast cancer cases with
the population controls. The results are presented as odds
ratios (ORs) generated from two-by-two tables. Confi-
dence intervals (CIs) are reported at the 95% significance
level.
326 J Appl Genetics (2011) 52:325–330Results
The most frequent BRCA1 mutation in the analysed
population, without the division into provinces, was
5382insC found in 29 out of 16,849 samples (0.17%).
300T >G and 3819del5 mutations were found in respec-
tively 11 out of 13,462 (0.08%) and four out of 3923
(0.10%) samples. 185delAG mutations were not found in
any of 12,485 analysed newborn samples. The population
frequencies for combined Polish founder 5382insC and
300T >G mutations without the division into provinces was
0.25% (1/400). As using a combination screening methods
these two mutations are detected in 70–90% of all BRCA1-
positive Polish families, we estimated the frequency of
BRCA1 mutations in general population of Poland at about
1/240–1/360.
Figure 2 shows the geographical distribution of analysed
mutations with the division of Poland into voivodeships.
We observed that the prevalence of recurrent mutations
varies according to the geographical origin of the collected
samples. For 5382insC mutation, the difference in frequen-
cy between three provinces was of statistical significance.
This genetic change was the most common in Warmia–
Mazury (10/2377, 0.42%) where it was significantly higher
than in Pomorze (0/2578, 0.0%) (p=0.001) and Malopolska
(2/2231, 0.09%) (p=0.028). For other analysed mutations,
the differences in frequency between provinces were not
statistically significant.
In the group of unselected breast cancers collected in
two provinces, Malopolska and Mazowsze, the most
frequent mutation was 5382insC (35/1845, 1.9%) followed
by 300T >G (18/1486, 1.2%). Comparing 5382insC
mutation frequency in breast cancer cases with the mutation
frequency detected in general newborn population of these
two provinces (5/4471), we calculate the relative risk of
breast cancer for this mutation at OR = 17 (95%CI 6.6–
43.4). For 300T >G missense mutation (2 out of 4352
control samples), the relative risk calculated in this way was
OR = 26 (95%CI 6.1–113.7).
Discussion
For BRCA1 and BRCA2 gene mutations controling large
scale series are limited by the relative low prevalence of
these mutations in the general population, as well as the
complexity and cost of analysis of thousands of control
subjects. A crucial factor in this type of studies is the
occurrence of population specific, recurrent mutations.
Our choice of four BRCA1 alleles analysed in the present
study reflects their high frequency among Polish multiple
breast and/or ovarian cancer families (Brozek et al. 2009;
Gorski et al. 2000; Grzybowska et al. 2000;J a s i n s k aa n d
Krzyzosiak 2001; Perkowska et al. 2003; Ratajska et al.
2008; Van Der Looij et al. 2000a). As a strong founder
effect is noted in Poland, two BRCA1 mutations, truncat-
ing 5382insC and missense 300T >G comprise 70–90% of
all BRCA1 pathogenic alterations. This finding allows for
rapid and relatively cheap DNA screening in Polish
population.
Fig. 1 The contributions the
mutation detection methods
made to analysis pathogenic
allels and representative exam-
ples of detected mutations.
a - representative gels showing
PCR products, b - representative
DHPLC chromatograms,
c - representative sequencing
results confirming the presence
of the mutations, RFLP -
restriction fragment length
polymorphism, SSCP - single-
strand conformation polymor-
phism, ASA-PCR - allele-
specific PCR, DHPLC -
denaturing high performance
liquid chromatography
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BRCA1/2 mutations occur with the frequency of 0.06–
0.24% (Antoniou et al. 2002;F o r de ta l .1995; Malone et al.
2006; Whittemore et al. 1997, 2004). Even though Hall et
al. (2009) reported that BRCA1/2 mutation prevalence is
remarkably similar among women who undergo genetic
testing across diverse ethnicities, in some populations the
frequency of mutations can be higher because of strong
founder effect. Relatively high prevalence of BRCA1
(0.32%) and BRCA2 (0.69%) mutations described in the
population of Ontario, Canada, can be caused by the
inclusion of subjects from groups that harbour frequent
founder mutations (Ashkenazi Jews and French Canadians)
(Metcalfe et al. 2010; Risch et al. 2006). In such countries
as Israel or Iceland, founder mutations account for the great
majority of deleterious BRCA1/2 mutations. The strongest
founder effect was noted in the Ashkenazi Jew population,
where two common mutations: 185delAG in BRCA1 and
6174delT in BRCA2 occur with cumulative frequency of
about 2–2.5% (Ferla et al. 2007; Neuhausen et al. 2009;
Struewing et al. 1997). The third relatively common
mutation in Ashkenazi Jews is 5382insC, described in this
population with the frequency of 0.12–0.32% (Struewing et
al. 1997; Fodor et al. 1998). Among the families with
multiple breast and ovarian cancers from Western and
Central Europe, this mutation is respectively two and four
times as common as 185delAG (Hall et al. 2009).
In our study of 16,849 anonymous newborns, 5382insC
mutation prevalence was 0.17%, so its frequency is similar
to that observed in Ashkenazi Jews, whereas 185delAG
mutations were not found in any of 12,485 analysed
samples. In population study presented by Gorski et al.
(2005) provided on the combined group of 4000 control
individuals from north-western Poland 5382insC mutation
occurred in 0.35% of analysed subjects. This mutation is
also prevalent in many European countries like Russia,
where it was detected in 94% of BRCA1 mutation carriers
(Loginova et al. 2003; Sokolenko et al. 2006), Germany
(22%) (Meindl et al. 2002), Czech Republic (37–40%)
(Foretova et al. 2004; Machackova et al. 2008), and
Lithuania (63%) (Csokay et al. 1999).
The second founder mutation for Polish population is
300T >G, detected in 0.082% of the analysed samples. In
the study provided by Gorski et al. (2005), this DNA
change was detected in 0.05% control subjects. 300T >G
mutation is regarded as the founder change in many Central
European countries, like Germany, Hungary, Lithuania,
Austria and Poland (Csokay et al. 1999; Kroiss et al. 2005;
Meindl et al. 2002; Van Der Looij et al. 2000b). We also
observed relatively high frequency of 3819del5 BRCA1
Fig. 2 Map of Poland
with division into voivodeships
showing geographical distribu-
tion and frequencies of BRCA1
5382insC, 300T >G, 185delAG,
and 3819del5 mutations.
* - only 5382insC mutation
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ovarian cancer families and in consecutive ovarian cancers
in this region (Brozek et al. 2008; Ratajska et al. 2008).
This mutation is also frequent in the Czech Republic, where
it was detected in 13–15% BRCA1-carriers (Foretova et al.
2004; Machackova et al. 2008). Data of DNA analysis
collected from Pomorze population will allow us to design
a wider panel of recurrent mutations (including 3819del5)
useful in providing efficient BRCA1 screening that may be
applicable to Polish breast and/or ovarian cancer families.
On the basis of an analysis of family area of origin
before the Second World War (WWII), Gorski et al. did not
notice any particular geographical aggregation of specific
BRCA1 mutations in different voivodeships of Poland
(Gorski et al. 2005). The present comparison of occurrence
of BRCA1 mutations in seven areas of Poland shows that
some mutations differ in their relative frequencies, although
the small number of positive samples does not allow us to
reach statistical significance. The low frequency of indi-
vidual mutations means that even large studies often detect
only a small number of carriers and, even when we analyse
relatively frequent founder changes, the estimates lack
precision. Polish population is not ethnically mixed,
because of the loss of a considerable number of ethnic
groups from Poland’s territory and the extensive resettle-
ments and mixing of Poles after WWII (Ploski et al. 2002).
In such ethnically homogeneous populations, for a more
precise estimation it is more valuable to present mutation
frequency for the population at large, without division into
voivodeships. Our studies embraced >16,000 samples,
which is, to date, the biggest ever published analysis of
BRCA1 mutation frequency and the mutation prevalence
estimated in this way seems to be the most precise.
The frequency of BRCA1/2-positive breast cancer cases
is evaluated at 2–5% (Gorski et al. 2005; John et al. 2007;
Kurian 2010; Malone et al. 2006; Sokolenko et al. 2006;
Whittemore et al. 2004) and it is in accord with our
observations. Comparing population frequency of 5382insC
mutation in Mazowsze and Malopolska (5/4471) with the
rate of BRCA1-carriers among consecutive breast cancer
patients (35/1845) in these provinces, we calculate the
relative risk of breast cancer for this mutation at OR = 17.
For missense 300T >G mutation (present in 18 out of 1486
breast cancer cases and in two out of 4352 control samples)
odds ratio calculated in this way is OR = 26. These odds
ratios are higher than estimated by Gorski et al. (2005),
who calculated the relative risk for 5382insC at OR = 6.2
and for 300T >G at OR = 15. In both studies, ours and
those provided by Gorski, the odds ratio for 300T >G
BRCA1 mutation was higher than for 5382insC mutation
but since BRCA1 mutations are relatively rare, estimations
calculated in this way lack precision. Knowing the breast
cancer risk in the population of Polish women, (0.047 by
the age of 70), and the odds ratio for 5382insC mutation,
we estimated penetrance for this mutation at 0.8. Our
evaluations are slightly higher than those earlier presented
for this mutation (Antoniou et al. 2005; Kroiss et al. 2005).
A combined analysis of several studies presented by
Antoniou et al. has shown that breast cancer lifetime risk
for 5382insC mutation in Ashkenazi Jews is 67% and
probably does not differ from the risk in non-Ashkenazi
Jewish women (Antoniou et al. 2005; Brose et al. 2002).
The advantages of our study include its large sample size
and direct mutation scanning in population controls,
whereas other large population-based studies extrapolated
population carrier prevalence from breast and/or ovarian
cancer case studies. We believe that random choice of
anonymous newborn samples creates the best control group
for estimation BRCA mutation prevalence in gthe eneral
population, because this type of study eliminates the
unwanted family selection present in studies based on
volunteers.
Conclusions
Our results, based on large population studies, show high
frequencies of founder 5382insC and 300T >G BRCA1
mutations in Polish general population. The population
prevalence for combined Polish founder 5382insC and
300T >G mutations was 0.25% (1/400). Carriage of one of
these mutations is connected with a very high relative risk
of breast cancer.
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